Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies, Volume I

153.3K

views

136

authors

18

articles

Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies, Volume I

153.3K

views

136

authors

18

articles

Editorial

25 September 2020

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies

Yiting Wang

,

Hubing Shi

,

Huan Meng

and

Jie Xu

3,080 views

1 citations

Editors

3

Fudan University

Sichuan University

National Center for Nanoscience and Technology, Chinese Academy of Sciences (CAS)

Impact

About

This Research Topic is part of a series with:
Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies, Volume II

As a therapeutic strategy, cancer immunotherapy is now increasingly popular, treating cancer through the utilization of the human immune system. These regimens include tumor vacancy, recombinant immune cytokines, adoptive T cell transplantation (T cell, TCRT, CART, etc.), as well as immune checkpoint blockade. The efficacy of cancer immunotherapy, however, was largely limited because tumor cells may develop multiple approaches to evade immune surveillance by hijacking the hosts immune system. In recent years, immune checkpoint blockade therapy (ICBT), which blocks tumor immune escape, has exhibited momentous clinical benefits, placing tumor immunotherapy under the spotlight. Several immune checkpoints have been discovered to be optimal targets for immune blockade, including the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) pathways. Nevertheless, not only the limited tumor response, usually between 5% to 40%, but also acquired drug resistance have been observed in patients receiving long term ICBT treatment, highlighting an urgent need to extend our understanding on the mechanisms that regulate anti-cancer immunity.

This Research Topic covers all aspects of cancer immunotherapy in this context, aiming to bring timely and significant discoveries to the research community.

This Research Topic is part of a series with:
Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies, Volume II

As a therapeutic strategy, cancer immunotherapy is now increasingly popular, treating cancer through the utilization of the human immune system. These regimens include tumor vacancy, recombinant immune cytokines, adoptive T cell transplantation (T cell, TCRT, CART, etc.), as well as immune checkpoint blockade. The efficacy of cancer immunotherapy, however, was largely limited because tumor cells may develop multiple approaches to evade immune surveillance by hijacking the hosts immune system. In recent years, immune checkpoint blockade therapy (ICBT), which blocks tumor immune escape, has exhibited momentous clinical benefits, placing tumor immunotherapy under the spotlight. Several immune checkpoints have been discovered to be optimal targets for immune blockade, including the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) pathways. Nevertheless, not only the limited tumor response, usually between 5% to 40%, but also acquired drug resistance have been observed in patients receiving long term ICBT treatment, highlighting an urgent need to extend our understanding on the mechanisms that regulate anti-cancer immunity.

This Research Topic covers all aspects of cancer immunotherapy in this context, aiming to bring timely and significant discoveries to the research community.

Download ebook

Share

Editors

Fudan University

Sichuan University

National Center for Nanoscience and Technology, Chinese Academy of Sciences (CAS)

Impact

153,307 Total views

103,632 Article views

46,280 Article downloads

3,395 Topic views

Published In

Journal Thumbnail

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Journal Thumbnail

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic